Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.

2.50
Hdl Handle:
http://hdl.handle.net/10757/622478
Title:
Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.
Authors:
Pichilingue-Febres, Alejandra F.; Arias-Linares, Miguel A.; Araujo-Castillo, Roger V.
Citation:
Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017. 2017 Breast Cancer Research and Treatment
Publisher:
Springer New York LLC
Journal:
Breast Cancer Research and Treatment
Issue Date:
21-Dec-2017
URI:
http://hdl.handle.net/10757/622478
DOI:
10.1007/s10549-017-4620-y
Additional Links:
http://link.springer.com/10.1007/s10549-017-4620-y
Abstract:
We would like to express our opinion regarding a Parise and Caggiano paper recently published in your journal. We certainly believe this is a great contribution, since it found that node-negative HER2 (+) breast cancer patients have better survival contrary to the common knowledge. This finding could reflect the consequences of targeted therapies that are changing the natural history of the disease. However, we think that such an interesting analysis could also have been done with stage III and IV patients, since this group of people could benefit greatly from these findings. In fact, new guidelines now recommend the use of HER2-specific therapy for stage IV patients with positive markers, even for life if they do not show signs of progression. Additionally, we would like to discuss the value of adding the Ki-67 marker to the classification proposed by the authors, because several papers consider it an important prognostic factor. © 2017 Springer Science+Business Media, LLC, part of Springer Nature
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/restrictedAccess
Language:
eng
Description:
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.
Keywords:
Breast neoplasms; Ki-67 Antigen; Receptor, ErbB-2; Survival analysis
ISSN:
0167-6806; 1573-7217

Full metadata record

DC FieldValue Language
dc.contributor.authorPichilingue-Febres, Alejandra F.es
dc.contributor.authorArias-Linares, Miguel A.es
dc.contributor.authorAraujo-Castillo, Roger V.es
dc.date.accessioned2018-01-03T21:58:32Z-
dc.date.available2018-01-03T21:58:32Z-
dc.date.issued2017-12-21-
dc.identifier.citationComments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017. 2017 Breast Cancer Research and Treatmentes
dc.identifier.issn0167-6806-
dc.identifier.issn1573-7217-
dc.identifier.doi10.1007/s10549-017-4620-y-
dc.identifier.urihttp://hdl.handle.net/10757/622478-
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.es
dc.description.abstractWe would like to express our opinion regarding a Parise and Caggiano paper recently published in your journal. We certainly believe this is a great contribution, since it found that node-negative HER2 (+) breast cancer patients have better survival contrary to the common knowledge. This finding could reflect the consequences of targeted therapies that are changing the natural history of the disease. However, we think that such an interesting analysis could also have been done with stage III and IV patients, since this group of people could benefit greatly from these findings. In fact, new guidelines now recommend the use of HER2-specific therapy for stage IV patients with positive markers, even for life if they do not show signs of progression. Additionally, we would like to discuss the value of adding the Ki-67 marker to the classification proposed by the authors, because several papers consider it an important prognostic factor. © 2017 Springer Science+Business Media, LLC, part of Springer Naturees
dc.formatapplication/flves
dc.language.isoenges
dc.publisherSpringer New York LLCes
dc.relation.urlhttp://link.springer.com/10.1007/s10549-017-4620-yes
dc.rightsinfo:eu-repo/semantics/restrictedAccesses
dc.subjectBreast neoplasmses
dc.subjectKi-67 Antigenes
dc.subjectReceptor, ErbB-2es
dc.subjectSurvival analysises
dc.titleComments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.es
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.journalBreast Cancer Research and Treatmentes
dc.description.peerreviewRevisión por pareses_PE
This item is licensed under a Creative Commons License
Creative Commons
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.